Novo Nordisk acquires SCD drug developer Forma Therapeutics

TAGS

Novo Nordisk acquisition of Forma Therapeutics : Danish pharma company has closed the previously announced $1.1 billion acquisition of Forma Therapeutics, a clinical-stage biopharma company focused on developing drugs for the treatment of (SCD) and rare blood disorders.

As per the terms of the deal announced last month, shareholders of the NASDAQ-listed Forma Therapeutics were offered $20 per share in cash by Novo Nordisk.

See also  Arch Oncology raises $50m to advance anti-CD47 antibody therapies

Following the completion of the deal, Forma Therapeutics is now a fully-owned subsidiary of the Danish pharma company and will be delisted from the Nasdaq Global Select Market.

Novo Nordisk acquires SCD drug developer Forma Therapeutics

Novo Nordisk acquires SCD drug developer Forma Therapeutics. Photo courtesy of Novo Nordisk A/S.

Forma Therapeutics’ lead development candidate is etavopivat, an oral, daily-once selective -R (PKR) activator. Etavopivat is being developed for improving the levels of and red blood cell health in patients having sickle cell disease.

See also  Padagis acquires former Emilia cosmetics facility in Yerucham, Israel

At the time of announcing the deal, Novo Nordisk said that the acquisition of Forma Therapeutics is in line with its strategy to complement and expedite its scientific footprint and pipeline in hemoglobinopathies.

CATEGORIES
TAGS
Share This